Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 78, 2018 - Issue 4
Submit an article Journal homepage
135
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Significance of asymptomatic hyperuricemia in patients after coronary events

Ivan TasićDepartment of Internal Medicine, Faculty of Medicine, University of Niš, Niš, Serbia; ;Institute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Svetlana KostićInstitute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Nikola M. StojanovićFaculty of Medicine, University of Niš, Niš, Serbia; Correspondence[email protected]
,
Vlado SkakićInstitute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Jovana CvetkovićInstitute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Aleksandar DjordjevićFaculty of Medicine, University of Niš, Niš, Serbia;
,
Mirjana KaradzićInstitute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Dragan DjordjevićDepartment of Internal Medicine, Faculty of Medicine, University of Niš, Niš, Serbia; ;Institute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Stanoje AndonovInstitute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Viktor StoičkovDepartment of Internal Medicine, Faculty of Medicine, University of Niš, Niš, Serbia; ;Institute for Therapy and Rehabilitation ‘Niška Banja’, Niška Banja, Serbia;
,
Dimitrije TasićAmerican University, Washington, DC, USA;
,
Meenakshi VankaJohns Hopkins University, Baltimore, MD, USA;
&
Dragan LovićVeterans Affairs Medical Center Washington USA, Washington, DC, USA
 show all
Pages 312-317 | Received 01 Mar 2018, Accepted 16 Apr 2018, Published online: 27 Apr 2018

References

  • Davis N. The cardiovascular and renal relations and manifestations of gout. JAMA. 1897;29:261–262.
  • Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–1821.
  • Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.
  • Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:e76.
  • Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–1551.
  • Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404–2410.
  • Deveci OS, Kabakci G, Okutucu S, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64:900–907.
  • Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759–766.
  • Nishida Y. Relation between creatinine and uric acid excretion. Ann Rheum Dis. 1992;51:101–102.
  • Messerli F, Frochlih E, Dreslinski G, et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93:817–821.
  • Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–697.
  • Sánchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237–247.
  • Li YH, Lin GM, Lin CL, et al. Relation of serum uric acid and body mass index to mortality in high-risk patients with established coronary artery disease: a report from the ET-CHD registry, 1997–2006. J Cardiol. 2013;62:354–360.
  • Norvik JV, Storhaug HM, Ytrehus K. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: the Tromsø study. BMC Cardiovasc Disord. 2016;16:85.
  • Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Ann Epidemiol. 1998;8:250–261.
  • Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19:1055–1062.
  • Matsubara K, Matsuzawa Y, Jiao S, et al. Relationship between hypertriglyceridemia and uric acid production in primary gout. Metab Clin Exp. 1989;38:698–701.
  • Kodama T, Murase T, Itakura H, et al. Post heparin plasma lipoprotein lipase and hepatic triglyceride lipase activities in patients with primary asymptomatic gout. Clin Chem. 1983;29:2124–2125.
  • Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23:NP1–NP96.
  • Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991–1997.
  • Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure – a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). J Cardiol. 2013;62:95–101.
  • Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16:15–24.
  • Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) Study. Circulation. 2015;131:1763–1771.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.